Prevalência de duplicação interna in tandem/fms-receptor tirosino-quinase (DIT/FLT3) em pacientes com leucemia mielóide aguda de novo classificados conforme grupos citogenéticos de risco by Krum, Everson Augusto et al.
Sao Paulo Med J. 2009; 127(1):23-7 23
O
rig
in
al
 a
rti
cle
Prevalence of FMS-like tyrosine kinase 3/internal tandem 
duplication (FLT3/ITD+) in de novo acute myeloid leukemia 
patients categorized according to cytogenetic risk
Prevalência de duplicação interna in tandem/fms-receptor tirosino-quinase (DIT/FLT3) em pacientes 
com leucemia mielóide aguda de novo classificados conforme grupos citogenéticos de risco
Everson Augusto Krum1, Mihoko Yamamoto2, Maria de Lourdes Lopes Ferrari Chauffaille2
Discipline of Hematology and Hemotherapy, Universidade Federal de São Paulo — Escola Paulista de Medicina (Unifesp-EPM), São Paulo, Brazil
1PhD. Professor, Universidade Estadual de Ponta Grossa (UEPG), Ponta Grossa, Paraná, Brazil.
2MD, PhD. Associate professor, Universidade Federal de São Paulo — Escola Paulista de Medicina (Unifesp-EPM), São Paulo, Brazil.
ABSTRACT
CONTEXT AND OBJECTIVE: The mechanism involved in leukemogenesis remains unclear and more information about the disruption of the cell proliferation, 
cell differentiation and apoptosis of neoplastic cells is required.
DESIGN AND SETTING: Cross-sectional prevalence study at the Discipline of Hematology, Hospital São Paulo, Universidade Federal de São Paulo.
METHODS: We investigated FMS-like tyrosine kinase 3/internal tandem duplication (FLT3/ITD+) in 40 adult patients with de novo acute myeloid leukemia 
(AML), categorized according to cytogenetic results, from September 2001 to May 2005.
RESULTS: Thirteen patients (32.5%) were classified as presenting the favorable karyotype, 11 patients (27.5%) as  an intermediate group, 7 patients 
(17%) as an undefined group and  9 patients (22.5%) as the unfavorable group. FLT3/ITD+ was found in 10 patients (25%): 3 with FLT3/ITD+ and 
favorable karyotype; 4 with FLT3/ITD+ and intermediate karyotype; 2 with FLT3/ITD+ and undefined karyotype; and only 1 with FLT3/ITD+ and unfavorable 
karyotype. Among the patients without FLT3/ITD+, 10 presented favorable karyotype, 8 intermediate, 4 undefined and 8 unfavorable karyotype. The 
cytogenetic results showed no correlations between FLT3/ITD presence and the prognostic groups (P = 0.13). We found that 2 patients were still alive 
more than 24 months later, FLT3/ITD+ did not influence the patients’ survival rate.
CONCLUSION: We found the same frequency of AML with FLT3/ITD+ in both the favorable and intermediate prognosis groups. Only one patient presented 
AML, FLT3/ITD+ and unfavorable karyotype (the hypothetical worst clinical situation). Therefore, the prognostic advantage of favorable cytogenetics among 
patients with FLT3/ITD+ remains to be elucidated, for it to be better understood.
RESUMO
CONTEXTO E OBJETIVO: O mecanismo envolvido na leucemogênese permanece obscuro, e maiores informações a respeito das inadequadas proliferação, 
diferenciação e apoptose das células neoplásicas é fundamental.
TIPO DE ESTUDO E LOCAL: Estudo transversal de prevalência na Disciplina de Hematologia e Hemoterapia, Hospital São Paulo, Universidade Federal de 
São Paulo.
MÉTODOS: Nós pesquisamos a duplicação interna in tandem (DIT) do gene FLT3 (Fms-like tyrosine kinase) em 40 pacientes adultos com leucemia 
mielóide aguda (LMA) de novo, classificados de acordo com os resultados de cariótipo em banda G, de setembro de2001 a maio de 2005.
RESULTADOS: Treze pacientes (32,5%) foram classificados como cariótipo favorável, 11 pacientes (27,5%) como grupo intermediário, 7 pacientes 
(17%) no grupo de prognóstico indefinido e os restantes 9 pacientes (22,5%) foram alocados como desfavorável. A DIT/FLT3 foi encontrada em 10 
pacientes (25%), 3 pacientes com DIT/FLT3 e cariótipo favorável, 4 com DIT/FLT3 e cariótipo intermediário, 2 com DIT/FLT3 e cariótipo de prognóstico 
indefinido e somente 1 paciente com DIT/FLT3 e cariótipo desfavorável. Entre os pacientes sem DIT/FLT3, 10 apresentaram cariótipo favorável, 8 com 
cariótipo intermediário, 4 com cariótipo de prognóstico indefinido e 8 com cariótipo desfavorável. Não houve correlação entre a presença de DIT/FLT3 e 
os grupos de prognóstico conforme resultados de citogenética (P = 0,13). No presente estudo encontramos 2 pacientes vivos por mais de 24 meses. A 
presença de DIT/FLT3 não influenciou a taxa de sobrevida dos pacientes.
CONCLUSÃO: Nós observamos a mesma frequência de LMA com DIT/FLT3 tanto no grupo de cariótipo favorável quanto no grupo intermediário e somente 
um paciente com LMA e DIT/FLT3 e cariótipo desfavorável, hipoteticamente o pior achado clínico. Desta forma, a vantagem prognóstica do cariótipo 
favorável em pacientes DIT/FLT3 permanece a ser esclarecida para melhor compreensão da LMA.
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INTRODUCTION
Acute myeloid leukemia (AML) is a clonal disorder that involves 
mutated hematopoietic precursors with inappropriate properties (e.g. 
uncontrolled proliferation, absence of apoptosis, abnormal cell differ-
entiation, etc.).1 The crucial question is which parts are defective in the 
multistep anomaly-generating process of genetic programming of AML 
cells. According to the “two hit” model of leukemogenesis,2 class I muta-
tions confer a proliferative and/or survival advantage to cells, while class 
II mutations give rise to impaired differentiation and abnormal apop-
tosis. Despite the important role of FMS-like tyrosine kinase 3/inter-
nal tandem duplication (FLT3/ITD+), a class I mutation, in providing 
a myeloproliferative signal and/or survival advantage to leukemia cells, 
this mutation does not affect differentiation by itself. Thus, for AML 
onset, additional class II mutations such as chromosome rearrange-
ments are probably required,3 e.g. promyelocytic leukemia-retinoic acid 
receptor-alpha (PML-RARα), core binding factor/smooth muscle myo-
sin heavy chain (CBFß/SMMHC), mixed-lineage leukemia (MLL) and 
acute myeloid leukemia-1 transcription factor/eight-twenty-one core-
pressor (AML1/ETO). These result in abnormalities relating to the 
CBF complex, MLL, Hox proteins and retinoic acid receptors.1
The FLT3 gene encodes an important tyrosine kinase receptor that 
is critical for normal hematopoiesis.4 FLT3/ITD+ 5 promotes disruption 
of a repressor sequence in the juxtamembrane domain of the FLT3 gene, 
leading to constitutive autophosphorylation of the receptor,6 thereby 
promoting proliferation and inhibiting apoptosis in leukemic cells.6,7 
FLT3/ITD+ is found in 20% to 30% of de novo AML patients7-10 and 
is the most mutated gene in leukemia, with a significant clinical impact 
on patients.11
We approached this subject by investigating FLT3/ITD+ in de novo 
AML patients categorized according to cytogenetic results, focusing es-
pecially on the group with favorable prognosis and normal karyotype, 
and associating this with age and white blood cell (WBC) count. 
METHODS
Patient samples
The eligible cases consisted of adult patients referred to Hospital 
São Paulo, Universidade Federal de São Paulo — Escola Paulista de Me-
dicina (Unifesp-EPM) from September 2001 to May 2005 (Table 1), 
with de novo AML according to World Health Organization diagnostic 
criteria.12 Immunophenotypic cell characterization was performed using 
a FACScalibur flow cytometer (Becton Dickinson, California, United 
States) with standardized monoclonal antibodies, in accordance with 
previously published protocols. The Unifesp Ethics Committee ap-
proved this study.
Cytogenetics
Chromosome analyses were performed on short-term non-stimu-
lated cultures from bone marrow cells. These were harvested after 24 
hours and slides from these cultures were banded using the Trypsin-Gi-
emsa technique (GTG).13 The metaphases were analyzed using an image 
capture system (Olympus BX microscope and Cytovision data process-
ing through Applied Biosystems). The abnormalities were described in 
accordance with the International System for Human Cytogenetic No-
menclature (ISCN).14 The karyotype results were categorized as the fol-
lowing prognostic groups: favorable, with t(8;21), t(15;17) or inv(16); 
intermediate, with normal karyotype or structural or numerical chang-
es not encompassed by the favorable or adverse risk groups; undefined, 
with metaphases unavailable; and unfavorable, with complex karyotype, 
monosomy of chromosome 5 or 7, deletions of the long arm of chromo-
some 5 or 3q abnormalities.15   
Polymerase chain reaction (PCR)
Deoxyribonucleic acid (DNA) from bone marrow cells was ob-
tained by means of proteinase K digestion, phenol-chloroform extrac-
tion and ethanol precipitation. This was then analyzed for the presence 
of FLT3/ITD+ by means of the polymerase chain reaction using pub-
lished primers (ITD/Dialab) for exons 14 and 15.16 The amplification 
products were analyzed on 2% agarose gel and stained with ethidium 
bromide.
RESULTS
Forty eligible patients were enrolled: 18 men and 22 women (male/
female ratio of 0.82). The median age was 52 years (range 21-91 years). 
Karyotyping was successful in the cases of 33 patients (83%), while sev-
en samples were unavailable (17%). According to the karyotyping re-
sults, the patients were classified into prognostic groups, stratified as 
shown in Table 1. 
Thirteen patients (32.5%) were classified as presenting a karyotype 
with a favorable prognosis: six with t(8;21) (cases 14, 21, 27, 33, 39 and 
40); four with t(15;17) (cases 1, 10, 11 and 18) and three with inv(16) 
(cases 23, 24 and 26). Eleven patients (27.5%) were placed in the inter-
mediate karyotype group: five with normal karyotype (cases 4, 12, 13, 
15 and 38); two with abnormalities of chromosome 1 (cases 16 and 22); 
one with isolated trisomy 8 (case 28); one with translocation of chro-
mosome 9 (case 29); one with translocation of chromosome 19 (case 
34); and one with abnormal chromosome 21 (case 2). Seven patients 
(17%) were placed in the undefined karyotype group (cases 5, 6, 9, 17, 
30, 32 and 36). The remaining nine patients (22.5%) were categorized 
in the unfavorable group: two patients with complex karyotype (cases 
3 and 25); two with abnormalities of chromosome 3 (cases 8 and 37); 
one with del(5q) and del(7p) (case 31); one with tetrasomy 8 (case 19); 
two with 11q23 abnormalities (cases 20 and 35) and one with trisomy 
22 and +14 (case 7).
FLT3/ITD+ was found in 10 patients (25%): three with FLT3/ITD+ 
and favorable karyotype; four with FLT3/ITD+ and intermediate karyo-
type; two with FLT3/ITD+ and undefined karyotype; and only one pa-
tient with FLT3/ITD+ and unfavorable karyotype. There was no differ-
ence in prognosis stratification group regarding presence or absence of 
FLT3/ITD+ (P = 0.13). Among the patients without FLT3/ITD+, 10 
presented favorable karyotype, eight intermediate, four undefined and 
eight unfavorable karyotype.
The median age of the patients with favorable karyotype was 38 
years, while it was 54 years in the unfavorable group. Patients with 
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FLT3/ITD+ had a median age of 54 years (range 22-87 years), while pa-
tients without FLT3/ITD+ had a median age of 53 years (range 21-91 
years) (P = 0.97). 
Patients with FLT3/ITD+ had a median white blood cell (WBC) 
count of 9.2 x 109/l (range: 0.6 x 109/l to 202 x 109/l) and patients with-
out FLT3/ITD+ had a median WBC count of 12.1 x 109/l (range: 1.9 
x 109/l to 240 x 109/l) (P = 0.22). Two patients with FLT3/ITD+ had 
a WBC count of up to 50 x 109/l, while seven patients without FLT3/
ITD+ had a WBC count of up to 50 x 109/l. The median WBC count 
of the patients with unfavorable karyotype was 21 x 109/l, while it was 
9.7 x 109/l in the intermediate group and 9.3 x 109/l in the group with 
favorable karyotype. Patients with FLT3/ITD+ had a mean WBC count 
of 30.4 x 109/l, while patients without FLT3/ITD+ had a mean WBC 
count of 45.3 x 109/l.
DISCUSSION
The real mechanism involved in the transformation from normal to 
leukemic cells remains unclear, and therefore some further light on this 
issue is needed. The presence of an abnormal karyotype in association 
with FLT3/ITD+ might be one factor implicated in leukemogenesis, al-
though not the only one. There is much evidence that chromosomal ab-
normalities and alterations to genomic DNA are implicated in deregu-
lated proliferation, escape of apoptosis or defective apoptosis and subse-
quent excessive survival of neoplastic cells. 
In the present study, we found that 25% of the patients presented 
FLT3/ITD+. According to the chromosomal abnormality classification, 
13 patients had a favorable karyotype: three (23%) with FLT3/ITD+ 
and 10 without mutations. Other studies have reported that patients 
Patient age/sex WHO criteria Karyotype Prognostic group stratification FLT3/ITD
1 21/M A 46,XY,t(15;17)(q22;q11) Favorable ITD -
2 71/F D 46,XX,add(21)(q22) Intermediate ITD -
3 50/F C
53-56,XX, +1,+8, +9,+10,i?(11)(q13), +14,+15, 
+16,+17,+18,+19, 6dmin[cp20]
Unfavorable ITD -
4 70/M B 46,XY Intermediate ITD+
5 70/F D Unavailable Undefined ITD -
6 73/F D Unavailable Undefined ITD -
7 62/M B 46,XY,+14,+22/46,XY Unfavorable ITD -
8 56/M D 46,XY,del(3)(q31)/46,XY Unfavorable ITD -
9 41/F D Unavailable Undefined ITD -
10 41/F A 46.XX,t(15;17)(q22;q12) Favorable ITD+
11 22/M A 46,XY,t(15;17)(q22;q11) Favorable ITD+
12 81/M D 46,XY Intermediate ITD -
13 80/F D 46,XX Intermediate ITD+
14 63/F A 46,XX,t(8;21)(q22;q22) Favorable ITD -
15 43/M B  46,XY Intermediate ITD -
16 46/M D 46,XY,t(1;2)(p31;q34) Intermediate ITD -
17 29/M D Unavailable Undefined ITD -
18 38/M A 46,XY,t(15;17)(q22;q21) Favorable ITD -
19 91/F B  48,XX,+8+8 Unfavorable ITD -
20 52/F A 46,XX,del(11)(q23)/46,XX Unfavorable ITD -
21 22/M A 46,XY,t(8;21)(q22;q22) Favorable ITD+
22 63/F D 46,XX,t(1;10)(q44;q43)/46,XX Intermediate ITD -
23 24/F A 47,XX,+9,inv(16)(p13;q22) Favorable ITD -
24 29/F A 46,XX,+8,inv(16)/47,XX,inv(16),+22 Favorable ITD -
25 75/F D 86~167, XXXX<7n>/46,XX Unfavorable ITD+
26 38/F A 46,XX,inv(16)(p13;q22)/46,XX Favorable ITD -
27 63/M A 46,XX,t(8;21)(q22;q22) Favorable ITD -
28 87/F B 47,XX,+8/46,XX Intermediate ITD+
29 29/M D 46,XY,t(9;11)(p22;q11.2) Intermediate ITD -
30 67/M D Unavailable Undefined ITD+
31 54/M D 45,X,-Y,del(5)(q15;q33),del(7)(p13) Unfavorable ITD -
32 35/F D Unavailable Undefined ITD+
33 52/F A 46,XX,t(2;13)t(8;21)(q22;q22) Favorable ITD -
34 73/F B  46,XX,der(19),t(1;19)(q21;p13)/46,XX Intermediate ITD -
35 30/M A 46,XY,del(11)(q23) Unfavorable ITD -
36 32/M D Unavailable Undefined ITD+
37 41/F D 47,XX,t(3;5)(q25;q34),+4 Unfavorable ITD -
38 78/F D 46,XX Intermediate ITD -
39 48/M A 46,XY,t(8;21)(q22;q22) Favorable ITD -
40 54/F A 46,XX,t(8;21)(q22;q22) Favorable ITD -
A = acute myeloid leukemia with recurrent chromosomal abnormalities; B = acute myeloid leukemia with multilineage dysplasia; C = acute myeloid leukemia after therapy (chemo or radio); D = acute myeloid leukemia not catego-
rized; M = male; F = female.
Table 1. Cytogenetic findings, World Health Organization (WHO) criteria, prognostic group stratification and presence of FMS-like tyrosine kinase 3/internal 
tandem duplication (FLT3/ITD) 
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with FLT3/ITD+ had a poor prognosis, but in our study, we found that 
cases 11 and 21 remained alive for 31 and 27 months respectively, while 
only one patient (case 10) had a short survival (one month) after diag-
nosis. In fact, FLT3/ITD+ did not influence the patients’ survival rate. 
The favorable chromosome rearrangement may have prevailed over the 
FLT3 gene mutation. 
Considering the importance and frequency of recurrent chromo-
somal abnormalities, AML with translocation t(8;21) results in an 
AML1/ETO fusion gene involved in blocking AML-1 dependent tran-
scription activation. It also blocks the activating effects of CCAAT/en-
hancer-binding protein-alpha (C/EBPα), which is responsible for dereg-
ulated cell differentiation.17,18 We found AML with t(8;21) in 14% of 
our patients and in one with FLT3/ITD+ (2.5%). This demonstrates that 
fusion rearrangement is not fundamental but contributes towards oth-
er genetic alterations such as mutations like FLT3/ITD+,19 and towards 
leukemic events in some situations that are not fully understood. In fact, 
we recently reported on one case of myelodysplastic syndrome (MDS) in 
a follow-up study. This patient underwent a transformation to leukemia 
with AML/ETO fusion and acquisition of FLT3/ITD+, thereby corrob-
orating Gilliland’s “two hit” hypothesis for leukemogenesis.20
The CBF complex acts on genes that are crucial for myeloid prolif-
eration. According to Reilly,21 potential leukemic cells have CBF fusion 
genes but another hit is required for AML development. In cases of in-
version of chromosome 16, the fusion protein CBFß/SMMHC is pro-
duced, which is a CBF inhibitor resulting in abnormal transcription of 
proliferative signals.6 In AML cases with inversion of chromosome 16, 
the consequence is inactivation of the CBFß protein, abnormal tran-
scription of the proliferative signal and blocking of cell maturation.6,17 
We observed AML with inv(16) in 7.5% of our patients and none with 
FLT3/ITD+. 
In leukemia with t(15;17), blocking of cell differentiation is a conse-
quence from the PML/RAR-α fusion protein, which leads to abnormal 
functioning of the retinoic acid receptor alpha.22 AML with t(15;17) 
was found in four of our patients (10% of the cases), and two of them 
had FLT3/ITD+. This feature corroborates other studies that found that 
about half of the patients had PML/RAR-α but did not have FLT3/
ITD+..9-11,19 With regard to patients with AML and normal karyotype, 
we observed that 12.5% of our patients had AML and normal karyo-
type, thus differing from other studies that found that 45-50% had nor-
mal karyotype.15,23,24 The incidence of FLT3/ITD+ and normal karyo-
type in the present study was 40%, while Whitman et al.25 reported this 
in 28% of their patients. Among the seven patients in our study with-
out metaphases available, we found that three had FLT3/ITD+ (42.8%), 
thus showing the need to apply several methods in order to comprehen-
sively identify the disease, using other resources such as the PCR tech-
nique to characterize AML patients.26
In our study, the data are conflicting. We did not find any statisti-
cal difference in mean WBC counts between FLT3/ITD+ patients and 
patients without FLT3/ITD+ (P = 0.224). The median WBC count of 
patients with an unfavorable karyotype was higher than in cases with an 
intermediate or favorable karyotype. This shows that the higher count 
for the unfavorable group is a further factor for a poor prognosis. There 
was no age difference between AML patients with FLT3/ITD+ and those 
without FLT3/ITD+, in agreement with a recent report by Levis and 
Small.11 Altogether, for patients with de novo AML, the best approach 
includes cytogenetic analysis and subsequent categorization into favor-
able, intermediate, undefined or unfavorable groups and investigation 
of FLT3/ITD+.24
CONCLUSION
In conclusion, we found the same frequency of AML with FLT3/
ITD+ in both the favorable and intermediate prognosis groups (3/10 
and 4/10 patients were positive, respectively). There was only one pa-
tient with AML, FLT3/ITD+ and unfavorable karyotype (i.e. the hypo-
thetical worst clinical situation). The prognostic advantage of favorable 
cytogenetics among patients with FLT3/ITD+ remains to be elucidated 
and the clinical significance is a matter of controversy. Thus, further in-
vestigation is warranted. 
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